Outcome measures in rheumatoid arthritis: The OMERACT process

Expert Review of Clinical Immunology

Volumn 3, Issue 3, 2007, Pages 271-275

  Brooks, Peter ^a   Boers, Maarten ^b   Simon, Lee S ^c   Strand, Vibeke ^d   Tugwell, Peter ^e  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Clinical end points; Clinical measurement; OMERACT; Outcome measures; Rheumatoid arthritis

Indexed keywords

ANTIRHEUMATIC AGENT;

ANKYLOSING SPONDYLITIS; ARTICLE; CLINICAL RESEARCH; CONSENSUS DEVELOPMENT; CONSTRUCT VALIDITY; CONTENT VALIDITY; CORRELATION COEFFICIENT; COST EFFECTIVENESS ANALYSIS; CRITERION RELATED VALIDITY; DISCRIMINANT ANALYSIS; DRUG SAFETY; ECONOMIC EVALUATION; FEASIBILITY STUDY; FIBROMYALGIA; FUNCTIONAL ASSESSMENT; GOUT; HEALTH ECONOMICS; HEALTH STATUS; HUMAN; MUSCULOSKELETAL DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOARTHRITIS; OSTEOPOROSIS; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PRACTICE GUIDELINE; PSORIATIC ARTHRITIS; QUALITY OF LIFE; RELIABILITY; RHEUMATIC DISEASE; RHEUMATOID ARTHRITIS; SCORING SYSTEM; UNSPECIFIED SIDE EFFECT; VALIDATION PROCESS;

EID: 34249714200     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/1744666X.3.3.271     Document Type: Article

References (28)

1. Bellamy N. Principles of outcome assessment. In: Rheumatology, 3rd Edition. Hochberg MC, Silman AJ, Smolen J-S, Weinblatt ME, Weisman MH (Eds). Mosby 21-30 (2003).
2. Boers M, Tugwell P, for the OMERACT Committee. Conference on Outcome Measures in Rheumatoid Arthritis Clinical Trials, Maastricht, The Netherlands, April 29-May 3, 1992. J. Rheumatol. 20, 525-591 (1993).
3. Boers M, Tugwell P, Felson DT et al. WHO and ILAR core endpoints for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials. J. Rheumatol. 21(Suppl. 41), 86-89 (1994).
4. Felson DT, Anderson JJ, Boers M et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. 38 (6), 727-735 (1995).
5. Prevoo MLL, van't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LBA, van Riel PLCM. Modified disease activity scores that include 28 joint counts. Arthritis Rheum. 38, 44-48 (1994).
6. Brooks PM, Day RO. Toxicity of antirheumatic drugs. J. Rheumatol. 22(5), 998-999 (1995).
7. Bellamy N, Boers M, Felson D et al. Health status instruments/ utilities. J. Rheumatol. 22, 1203-1207 (1995).
8. Drummond M, O'Brien B, for the Economics Workgroup. Economic analysis alongside clinical trials: practical considerations. J. Rheumatol. 22(7), 1418-1419 (1995).
9. Bellamy N, Kirwan J, Boers M et al. Recommendations for a core set of outcome measures for future Phase III clinical trials in knee, hip, and hand osteoarthritis. Consensus development at OMERACT III. J. Rheumatol. 24, 799-802 (1997).
10. Newman SP: Psychosocial measures in musculoskeletal trials. J. Rheumatol. 24, 979-984 (1997).
11. Sambrook PN, Cummings SR, Eisman JA et al. Guidelines for osteoporosis trials. J. Rheumatol. 24(6), 1234-1236 (1997).
12. Wells G, Boers M, Shea B et al. Sensitivity to change of generic quality of life instruments in patients with rheumatoid arthritis: preliminary findings in the generic health OMERACT study. J. Rheumatol. 26, 217-221 (1999).
13. Strand V, Gladman D, Isenberg D et al. Outcome measures to be used in clinical trials in systemic lupus erythematosus. J. Rheumatol. 26, 490-497 (1999).
14. van Gestel AM, Anderson JJ, van Riel PLCM et al. ACR and EULAR improvement criteria have comparable validity in rheumatoid arthritis trials. J. Rheumatol. 26, 705-711 (1999).
15. Molenaar E, Boers M, van der Heijde D et al. Imaging in rheumatoid arthritis: results of group discussions. J. Rheumatol. 26, 749-751 (1999).
16. van der Heijde D, van der Linden S, Dougados M et al. Ankylosing spondylitis: plenary discussion and results of voting on selection of domains and some specific instruments. J. Rheumatol. 26(1), 1003-1005 (1999).
17. Kirwan J, Heiberg T, Hewlett et al. Outcomes from the Patient Perspective Workshop at OMERACT 6. J. Rheumatol. 30, 868-872 (2003).
18. Gabriel S, Drummond M, Maetzel A et al. OMERACT 6 economics working group report: a proposal for a reference case for economic evaluation in rheumatoid arthritis. J. Rheumatol. 30, 886-890 (2003).
19. van der Heijde DMFM, Sharp JT, Rolf R et al. OMERACT workshop: repair of structural damage in rheumatoid arthritis. J. Rheumatol. 30, 1108-1109 (2003).
20. McQueen F, Lassere M, Edmonds J et al. OMERACT rheumatoid arthritis magnetic resonance imaging studies. Summary of OMERACT 6 MR imaging module. J. Rheumatol. 30, 1387-1392 (2003).
21. Wells GA, Boers M, Shea B et al. Minimal disease activity for rheumatoid arthritis: a preliminary definition. J. Rheumatol. 32, 2016-2024 (2005).
22. Lassere MND, Johnson KR, Boers M et al. Standardized assessment of adverse events in rheumatology clinical trials: summary of the OMERACT 7 drug safety module update. J. Rheumatol. 32, 2137-2141 (2005).
23. van der Heijde DMFM, Landewe RBM, Hermann K-GA et al. Application of the OMERACT filter to scoring methods for magnetic resonance imaging of the sacroiliac joints and the spine. Recommendations for a research agenda at OMERACT 7. J. Rheumatol. 32, 2042-2047 (2005).
24. Gladman DD, Mease PJ, Krueger G et al. Outcome measures in psoriatic arthritis. J. Rheumatol. 32, 2262-2269 (2005).
25. Mease PJ, Clauw DJ, Arnold LM et al. Fibromyalgia syndrome. J. Rheumatol. 32, 2270-2277 (2005).
26. Boers M, Tugwell P, Felson D et al. World Health Organisation and International League of Associations for rheumatology core end points for symptom modifying antirheumatic drugs in rheumatoid arthritis clinical trials. J. Rheumatol. 21(Suppl. 41), 86-89 (1994).
27. Felson DT, Anderson JJ, Boers M et al. The American College of Rheumatology preliminary core set of disease activity markets for rheumatoid arthritis clinical trials. Arthritis Rheum. 36, 729-740 (1993).
28. Felson DT, Anderson JJ, Lange MLM et al. should improvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures rather than twenty per cent? Arthritis Rheum. 41, 1564-1570 (1998).